{"id":"huminsulin-regular","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a short-acting insulin produced through recombinant DNA technology that mimics endogenous human insulin. It binds to insulin receptors on muscle, fat, and liver cells, facilitating glucose transport into these tissues and promoting glycogen synthesis while inhibiting gluconeogenesis. It is typically used for mealtime glucose control in diabetes management.","oneSentence":"Huminsulin Regular is a recombinant human insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:40:42.094Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02634528","phase":"PHASE1","title":"Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin N and Huminsulin® Basal","status":"COMPLETED","sponsor":"Julphar Gulf Pharmaceutical Industries","startDate":"2016-11-16","conditions":"Diabetes Mellitus","enrollment":85},{"nctId":"NCT02739906","phase":"PHASE1, PHASE2","title":"A Trial to Investigate Post Prandial Blood Glucose Control With Fast-acting Human Insulin HinsBet® Compared to Insulin Lispro (Humalog®) and Regular Human Insulin (Huminsulin® Normal) After Ingestion of a Standardized Meal in Subjects With T1DM","status":"COMPLETED","sponsor":"Adocia","startDate":"2016-04","conditions":"Type 1 Diabetes Mellitus","enrollment":36},{"nctId":"NCT00993473","phase":"PHASE3","title":"6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-10","conditions":"Type 1 Diabetes Mellitus","enrollment":125},{"nctId":"NCT00985712","phase":"PHASE4","title":"A Study on the Effect of 2 Pen Devices on HbA1c","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-10","conditions":"Diabetes Mellitus, Type 1","enrollment":263}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Huminsulin Normal","LY041001"],"phase":"marketed","status":"active","brandName":"Huminsulin Regular","genericName":"Huminsulin Regular","companyName":"Eli Lilly and Company","companyId":"eli-lilly-and-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Huminsulin Regular is a recombinant human insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}